Literature DB >> 12054060

5-HT2A antagonists in psychiatric disorders.

Luisa de Angelis1.   

Abstract

Several lines of evidence support a role for serotoninergic (5-HT) system abnormalities in the pathogenesis and treatment of several psychiatric disorders. This review summarizes information about the association between the 5-HT2A receptor gene and its relevance to schizophrenia, tardive dyskinesia, major depression, suicidality, anorexia nervosa and obsessive-compulsive disorder. Evidence is presented that implies that selective 5-HT2A antagonists may be considered useful in investigating the role of 5-HT2A receptor function and in the treatment of psychosis, and possibly alcohol and cocaine dependence. Additionally, findings are reviewed on the importance of 5-HT2A receptor antagonism in contributing to the therapeutic effect of several clinically effective and potential atypical antipsychotics as well as several antidepressants. In conclusion, the ability of selective 5-HT2A receptor antagonists to interfere with the heightened state of dopamine activity without altering basal tone, suggests that these drugs possess antipsychotic activity and may provide the basis for new therapies for psychosis and drug dependence, in addition to contributing towards a more complete understanding of 5-HT2A receptor function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12054060

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  10 in total

1.  5-HT2A receptor antagonist M100907 reduces serotonin synthesis: an autoradiographic study.

Authors:  Shu Hasegawa; Maraki Fikre-Merid; Mirko Diksic
Journal:  Brain Res Bull       Date:  2011-10-25       Impact factor: 4.077

Review 2.  Integrins in synapse regulation.

Authors:  Yun Kyung Park; Yukiko Goda
Journal:  Nat Rev Neurosci       Date:  2016-11-04       Impact factor: 34.870

3.  Evaluation of structural effects on 5-HT(2A) receptor antagonism by aporphines: identification of a new aporphine with 5-HT(2A) antagonist activity.

Authors:  Shashikanth Ponnala; Junior Gonzales; Nirav Kapadia; Hernan A Navarro; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2014-03-04       Impact factor: 2.823

4.  EMD 281014, a specific and potent 5HT2 antagonist in humans: a dose-finding PET study.

Authors:  David Mamo; Ewen Sedman; Joachim Tillner; Edward M Sellers; Myroslava K Romach; Shitij Kapur
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

5.  The stimulus effects of 8-OH-DPAT: evidence for a 5-HT2A receptor-mediated component.

Authors:  C J Reissig; J R Eckler; R A Rabin; K C Rice; J C Winter
Journal:  Pharmacol Biochem Behav       Date:  2007-09-19       Impact factor: 3.533

6.  Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats.

Authors:  Avi E Zayara; Gregor McIver; Paola N Valdivia; Kevin D Lominac; Andrew C McCreary; Karen K Szumlinski
Journal:  Psychopharmacology (Berl)       Date:  2010-09-03       Impact factor: 4.530

Review 7.  AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders.

Authors:  Alexandre V Ivachtchenko; Yan Lavrovsky; Ilya Okun
Journal:  J Alzheimers Dis       Date:  2016-05-25       Impact factor: 4.472

Review 8.  Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.

Authors:  Igho J Onakpoya; Carl J Heneghan; Jeffrey K Aronson
Journal:  BMC Med       Date:  2016-11-29       Impact factor: 8.775

9.  Association Study of a Serotonin Receptor 2A Gene -1438A/G Polymorphism and Anxiety-Related Traits.

Authors:  Kye-Hyun Kim; Hee-Yeon Woo; Se-Won Lim
Journal:  Psychiatry Investig       Date:  2008-12-31       Impact factor: 2.505

10.  Exercise benefits brain function: the monoamine connection.

Authors:  Tzu-Wei Lin; Yu-Min Kuo
Journal:  Brain Sci       Date:  2013-01-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.